Background. Interleukin (IL)-7 levels are increased in patients with human immunodeficiency virus type 1 (HIV-l)-associated lymphopenia; however, the effects of this on IL-7 receptor (IL-7R) expression, disease progression, and immune reconstitution remain unclear.
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NOTE. Data are median (interquartile range), unless otherwise noted. CHI, chronic HIV-l infection; lTNP-c, long-term non progressive HIV-l infection with viral control and CD4+ T cell counts~400 celis/ill; lTNP-loc, long-term non progressive HIV-1 infection with CD4+ T cell counts <400 celis/ill and loss of viral control; PHI, primary HIV-l infection; ... , information unavailable.
a For the comparison between patients with PHI and those with CHI. b For the comparison between patients with lTNP-c and those with lTNP-loc.
Circulating IL-7 levels are increased in lymphopenic conditions, including chronic HIV-l infection (CHI), and inversely correlate with total and naive CD4+ T cell counts [17] [18] [19] , suggesting that IL-7 production is up-regulated to counter CD4+ T cell loss. The use of animal models has shown that IL-7 drives immune reconstitution by increasing both thymic output [20, 21] and extrathymic proliferation [22] .
The benefits of increased IL-7 levels remain unclear. Low IL-7 levels, despite severe lymphopenia, are associated with poor immune reconstitution [23] , whereas high levels of expression of IL-7 and CD127 have been associated with successful immune reconstitution in patients with CHI after the initiation of antiretroviral therapy (ART) [24] . Although a positive correlation between baseline IL-7level and CD4+ T cell count after 20 months of ART has been reported [25] , others have found that IL-7 levels do not normalize after the initiation of ART, suggesting that immune reconstitution may be limited by other factors [26] . Furthermore, recent trials in which supraphysiological doses of IL-7 were administered to simian immunodeficiency virus-infected macaques found expanded peripheral CD4+ T cell populations [27, 28] . On balance, the available data suggest that IL-7 plays an important role in driving ARTmediated immune reconstitution.
Decreased sensitivity of CD8+ cytotoxic T lymphocytes (CTLs) to IL-7 during CHI is associated with decreased cellsurface CD127 expression [29] . This loss of CD127 expression may result from transient down-regulation after antigen-induced T cell activation [30] , which is consistent with the fact that CHI is a state of T cell hyperactivation [31] . CD127 expression on CTLs is partially restored by the administration of ART [32] .
The mechanisms that regulate the expression of IL-7R components remain unclear. CD127 is down-regulated on T cells after exposure to IL-2 [33] in vitro but not in vivo [34] . IL-7 administration down-regulates CD127 in animal models [27, 35] . Conversely, CD127 is up-regulated by administration of glucocorticoids [36] .
We investigated the effect of increased IL-7 levels on human T cell-surface expression of CD127 and CD132 in vitro and ex vivo. We investigated whether perturbations in the IL-7/IL-7R system during HIV-l infection were solely a chronic disease phenomenon by studying patients with primary HIV-l infection (PHI), CHI, and long-term nonprogressive HIV-l infection (LTNP), both before and after the loss of viral control. We hypothesized that early dysregulation of the IL-7/IL-7R system may be related to disease progression and may limit immune reconstitution.
PATIENTS, MATERIALS, AND METHODS

Patients. Therapy-naive patients with PHI (n = 25) or CHI
(n = 25) were enrolled in clinical trials of combination ART, and patients with LTNP (n = 10) and healthy controls (n = 18) were studied using cryopreserved plasma and peripheral blood mononuclear cells (PBMCs). Patients with PHI had confirmed, recent HIV-l infection by documented seroconversion illness and incomplete Western blot or a negative HIV-l test within the preceding 6 months [37] . Patients with CHI had been infected with HIV-l for >6 months, were treatment naive, and had detectable viral loads on recruitment. There were no significant differences in virological or immunological responses between patients receiving different treatment regimens [38] . Patients were studied at baseline and at 40 (PHI) or 48 (CHI) weeks after the initiation of ART. Patients with PHI had a significantly lower median age and higher total lymphocyte count, CD4+ T cell count, and CD8+ T cell count, compared with patients with CHI (table 1). The study protocol was reviewed and approved by the institutional review board at St. Vincent's Hospital, Sydney, Australia. Informed consent was obtained from each volunteer, in accordance with guidelines of both the local institution and the US Department of Health and Human Services.
Patients with LTNP were enrolled in the Sydney LTNP cohort [39] ; the inclusion criteria were HIV-l infection for >9 years with sustained CD4+ T cell counts ?'400 cells/ttL in the absence of ART. Five patients with LTNP during regular follow-up had Circulating IL-7 levels are increased in lymphopenic conditions, including chronic HIV-l infection (CHI), and inversely correlate with total and naive CD4+ T cell counts [17] [18] [19] , suggesting that IL-7 production is up-regulated to counter CD4+ T cell loss. The use of animal models has shown that IL-7 drives immune reconstitution by increasing both thymic output [20, 21] and extrathymic proliferation [22] .
PATIENTS, MATERIALS, AND METHODS
Patients. Therapy-naive patients with PHI (n = 25) or CHI
Patients with LTNP were enrolled in the Sydney LTNP cohort [39] ; the inclusion criteria were HIV-l infection for >9 years with sustained CD4+ T cell counts ?'400 cellS/ttL in the absence of ART. Five patients with LTNP during regular follow-up had signs of disease progression, with CD4+T cell counts <400 cells/ ILL and loss of viral control (median time to progression, 11 years; LTNP-loc). These patients were matched with 5 patients with LTNP who maintained viral control and CD4+ T cell counts~400 cells/ilL during the follow-up period (LTNP-c). The time points examined were cohort entry and 1-2 years after the loss of viral control (time point 2). At time point 2, all patients with LTNP-loc had received ART. At cohort entry, patients with LTNP-c had a significantly lower median age than did patients with LTNP-loc but were matched for CD4+ T cell count and viral load (table 1) .
Isolation of cell populations and cell culture conditions for in vitro studies. PBMCs from healthy volunteers were separated by density centrifugation from whole blood, as described elsewhere [40] . A total of 1 X 10 6 PBMCs were cultured for up to 7 days at 37°C in a humidified atmosphere with 5% CO 2 , in the presence of 0-10 ng/mL IL-7 (R&D Systems), in 24-well plates (Falcon; Becton Dickinson), in 1 mL ofIscove's modified Dulbecco's medium/lO% pooled human serum (gift from Wayne Dyer, Australian Red Cross Blood Services). In some experiments, exogenous IL-7 was removed after 24 h, and de novo protein synthesis was inhibited using cycloheximide (50 IlmollL; Sigma).
Measurement ofplasma IL-7Ievels. IL-71evels were measured, by ELISA, in cryopreserved plasma, using a commercial kit (R&D Systems) in accordance with the manufacturer's instructions; samples were run in duplicate.
Flow cytometry. CD4+ T cell subsets were identified by 5-and 6-color flow cytometry using PBMCs, as described elsewhere [41] , using the following monoclonal antibodies (MAbs): CD3-peridinin chlorophyll protein complex-Cy5.5, CD4-phycoerythrin (PE)-Cy7 (Becton Dickinson), CD127-PE (Beckman Coulter), CD45RO-fluorescein isothiocyanate, CD45RA-allophycocyanin (APC), and CD132-biotin (Pharmingen) with streptavidin (SA)-Cy5 (Jackson ImmunoResearch). CD8+ T cells were defined as CD3+CD4-lymphocytes. Intracellular staining was performed after cell-surface staining and incubation with FACS permeabilizing solution (Becton Dickinson), as described elsewhere [41] , using the following MAbs: Ki-67-PE, Bcl-2-PE (both from Pharmingen), CD132-biotin, and SA-Cy5 or CDl27-PE. After fixation, in vitro cell culture experiments were analyzed on a Coulter EPICS XL. Samples from patients were analyzed on a duallaser LSRII (Becton Dickinson) running FACSDiva software (version 5), as described elsewhere [41] .
Statistics. Differences between groups were determined using the unpaired nonparametric Mann-Whitney rank test; in longitudinal analyses, Wilcox signed rank tests were used. Correlations were determined by use of Spearman's correlation tests. All analyses were performed using StatView data analysis and presentation software (version 5.0; Abacus Concepts).
P< .05 was considered to be statistically significant. P values were not corrected for multiple comparisons. Correlation of plasma IL-7 levels with lymphocyte populations. We sought to examine whether published inverse correlations between plasma IL-7 levels and lymphocyte populations occurred in patients with PHI. Across the patient cohort, pretherapy plasma IL-7 level was significantly inversely correlated to total lymphocyte count, CD4+ T cell count, and CD8+ T cell count but not to viral load or age. When the patient cohort was split on the basis of PHI or CHI, these correlations occurred only in the CHI cohort ( signs of disease progression, with CD4+T cell counts <400 cells/ ILL and loss of viral control (median time to progression, 11 years; LTNP-loc). These patients were matched with 5 patients with LTNP who maintained viral control and CD4+ T cell counts~400 cells/ilL during the follow-up period (LTNP-c). The time points examined were cohort entry and 1-2 years after the loss of viral control (time point 2). At time point 2, all patients with LTNP-loc had received ART. At cohort entry, patients with LTNP-c had a significantly lower median age than did patients with LTNP-loc but were matched for CD4+ T cell count and viral load (table 1) .
RESULTS
Plasma
Measurement ofplasma IL-7Ievels
. IL-71evels were measured, by ELISA, in cryopreserved plasma, using a commercial kit (R&D Systems) in accordance with the manufacturer's instructions; samples were run in duplicate.
P< .05 was considered to be statistically significant. P values were not corrected for multiple comparisons.
RESULTS
Plasma IL-7 levels in patients with PHI and those with CHI.
We confirmed that patients with CHI have significantly increased plasma IL-7 levels before therapy (median, 3.07 pg/ mL), compared with healthy volunteers (median, 1.25 pg/mL) (P< .001). In patients with CHI, plasma IL-7 levels remained significantly increased after 48 weeks of ART (median, 2.05 pg/ mL; P< .01). Despite significantly higher CD4+ T cell counts, patients with PHI also had increased plasma IL-7 levels before therapy (median, 2.35 pg/mL; P< .01), compared with healthy volunteers. After 40 weeks of ART, IL-7 levels in patients with PHI had normalized (median, 1.46 pg/mL; P = .67).
Correlation of plasma IL-7 levels with lymphocyte populations. We sought to examine whether published inverse correlations between plasma IL-7 levels and lymphocyte populations occurred in patients with PHI. Across the patient cohort, pretherapy plasma IL-7 level was significantly inversely correlated to total lymphocyte count, CD4+ T cell count, and CD8+ T cell count but not to viral load or age. When the patient cohort was split on the basis of PHI or CHI, these correlations occurred only in the CHI cohort (table 2) . plasma IL-7 level and either absolute CD4+ T cell count or change in CD4+ T cell count after therapy in patients with CHI were noted (table 2) .
Relationship between pretherapy plasma IL-7 levels and
Differential regulation of cell-surface expression of CD127 and CD132. Preliminary investigations using whole blood revealed decreased cell-surface CD127 expression on CD45RO+CD4+ and CD8+ T cells from patients with PHI and patients with CHI (data not shown). The finding of early increases in plasma IL-7 levels in combination with down-regulation of CD127 in patients with HIV-l infection prompted us to examine more closely the relationship between IL-7 and CD127 expression in vitro. Culturing of PBMCs with IL-7 (10 ng/mL) resulted in the down-regulation of CD127, but not CD132, within 4-5 h. Before the addition of IL-7, >70% of CD4+ T cells expressed CD127. After 5 and 24 h of culture with IL-7, 15% and 5%, respectively, of CD4+T cells expressed CD127. Unless IL-7 was removed, CD127 was not reexpressed after CD4+ T cells had been cultured for 7 days (figure lA).
The extent and rapidity of CD127 down-regulation appeared to be dose dependent at 4 h, but, over the weeklong study period, it resembled a threshold effect after the addition of 10 ng/mL IL-7 (figure lB). In contrast, cell-surface CD132 expression increased from 6% to 19% of CD4+ T cells over 7 days in cultures with IL-7 (figure lA).
Staining of permeabilized PBMCs did not reveal an intracellular localization of CD127 expression either 4 h or 7 days after the addition of IL-7 (figure lA). Permeabilized PBMCs from control cultures exhibited high levels of intracellular CD132, which were not altered on incubation with IL-7 (figure lA) . This finding was confirmed using a directly conjugated antibody to CD132. Isotype controls and incubation with SA-APC alone were used to exclude nonspecific binding (data not shown). A. C04+ T cell expression of C0127, which is extracellular, and of C0132, which is largely intracellular. Unstimulated (US)
C04+ T cells at day 0 have high levels of cell-surface expression of C0127 (i) and low levels of expression of C0132 (ii). After day 7, with the addition of 10 ng/mL IL-7, cells had greatly reduced cell-surface C0127 expression (iii) and increased cell-surface C0132 expression (iv). Permeabilization of cells on day 7 after incubation with IL-7 resulted in no increase in C0127 expression (v) and a large increase in C0132 expression (vi). B, Demonstration that C04+ T cell-surface expression of C0127 is down-regulated by IL-7 after a threshold of 10 ng/mL is reached (i). This down-regulation is rapidly reversible and requires de novo protein synthesis (ii). There is evidence of C0127 turnover on the cell surface in the absence of IL-7 (iii). CFSE, carboxyfluorescein diacetate succinimidyl ester; PE, phycoerythrin. plasma IL-7 level and either absolute CD4+ T cell count or change in CD4+ T cell count after therapy in patients with CHI were noted (table 2) .
C04+ T cells at day 0 have high levels of cell-surface expression of C0127 (i) and low levels of expression of C0132 (ii). After day 7, with the addition of 10 ng/mL IL-7, cells had greatly reduced cell-surface C0127 expression (iii) and increased cell-surface C0132 expression (iv). Permeabilization of cells on day 7 after incubation with IL-7 resulted in no increase in C0127 expression (v) and a large increase in C0132 expression (vi). B, Demonstration that C04+ T cell-surface expression of C0127 is down-regulated by IL-7 after a threshold of 10 ng/mL is reached (i). This down-regulation is rapidly reversible and requires de novo protein synthesis (ii). There is evidence of C0127 turnover on the cell surface in the absence of IL-7 (iii). CFSE, carboxyfluorescein diacetate succinimidyl ester; PE, phycoerythrin.
both inhibited reexpression of CD 127 after IL-7 removal ( figure  1B) and reduced the proportion of CD12r T cells ( figure 1B) .
Cell-surface expression of IL-7R components in patients with HIV-l infection.
The differential regulation of CD127 and CD132 by IL-7 in vitro prompted an examination of the association between increased plasma IL-7 levels in vivo and expression of both receptor chains on PBMCs ex vivo. Healthy volunteers had 4 distinct populations of both CD4+ and CD8+ T cells, on the basis of CD127 and CD132 expression ( figures  2A and 2B and 3) . The majority of CD4+ T cells were CD12r132+ T cells (median, 52%); the second largest population was CD127+13T T cells (median, 42%). There were minor populations of CD12T132+ and CD12T13T CD4+ T cells (3% in both cases). Similar proportions were seen in the CD8+ subset: CD8+12r132+ (38%) and and minor CD8+12T13Y and CD8+12T13T populations (3% in both cases).
PHI was associated with a significant decrease in the percentage of CD4+127+13T T cells and an increase in the percentage of CD4+12T132+ T cells. These changes were even more pronounced in patients with CHI ( figure 3A) and were evident in both CD45RO-and CD45RO+ subsets. The populations did not normalize after 40-48 weeks of ART in either group (table 3) . There were no significant changes in either the CD4+127+132+ or the CD4+12T13T population.
In the CD8+ T cell subset, PHI was associated with decreases in the proportion of both CD12r132+ and CD127+13T populations and an increase in the proportion of CD12T132+ T cells. Again, these changes were more pronounced in patients with CHI ( figure 3B ) and did not normalize after the administration of ART.
Permeabilization of PBMCs revealed intracellular localization of CD132, but not CD127. The mean fluorescence intensities (MFIs) of cell-surface CD127 in healthy volunteers and patients were 825 and 811, respectively. The MFIs of cell-surface CD132 in healthy volunteers and patients were 425 and 631, respectively. Permeabilization of cells resulted in no significant change in CD127 MFI but did result in a massive increase in CD132 MFI-to 4277 in healthy volunteers (P< .05; figure 2C and 2D) and to 6024 in patients with HIV-1 infection (data not shown).
Correlation between cell-surface expression of IL-7R components and plasma IL-7 levels. The association between plasma IL-7 levels and changes in T cell subsets were examined before therapy in healthy volunteers, patients with PHI, and patients with CHI. Plasma IL-7 levels positively correlated with 
Correlation between cell-surface expression of IL-7R components and HIV-l disease progression.
To further examine the relationship between these novel CD4+ T cell subsets and disease progression, we examined the correlation between IL-7R expression and CD4+ T cell counts before therapy. In the combined PHI and CHI cohorts, CD4+127+13T T cell percentage positively correlated with CD4+ T cell count (p = 0.428; P< .05). There was a stronger inverse correlation between CD4+12T132+ T cell percentage and CD4+ T cell count Survival and turnover of CD12r13T T cells. The large proportion of both CD4+ and CD8+ CD12T T cells prompted us to define the survival and turnover characteristics of these cells. We examined the expression of antiapoptotic protein Bcl-2, a necessary component for T cell survival and a known target of IL-7, and of the cell-cycle protein Ki-67. HIV-1 infection was associated with an increase in CD12TBcl-T and CD12TKi-6r CD4+ and CD8+ T cells, which is consistent with the results of previous work [42] (data not shown).
Plasma IL-7 levels in patients with LTNP. Patients with LTNP with preserved CD4+ T cell counts were studied in an attempt to distinguish the effect of HIV-1 infection directly, as opposed to its effect on CD4+ T cell lymphopenia. To examine how IL-7/IL-7R expression related to HIV-1 progression, we selected a group of patients with LTNP, half of whom went on to lose viral control at follow-up. At cohort entry, patients with LTNP had plasma IL-71evels that were not significantly different from those of healthy volunteers (median, 1.01 pg/mL). Plasma IL-7 levels in patients with LTNP-c did not change over the observation period. In contrast, patients with LTNP-loc displayed a significant increase in plasma IL-7 levels from cohort entry to time point 2, after the loss of viral control (median, 1.01 and 1.86 pg/mL, respectively; P< .05).
Perturbations in T cell expression of IL-7R in patients with LTNP before and after loss of viral control.
Despite normal CD4+ T cell counts, patients with LTNP-c displayed an increased proportion of CD4+12T132+ T cells at cohort entry, compared with healthy volunteers (median, 8%; P< .05), suggesting that this perturbation occurs first among CD4+ T cells after HIV-1 infection. Interestingly, at cohort entry, patients with LTNP-loc had increased CD12T132+ (median, 19%; P< .01) and decreased CD4+12r13T (median, 13%; P< .01) T cell subsets. These changes occurred in both the CD4+RO-subset and the CD4+RO+ subset (table 3) both inhibited reexpression of CD 127 after IL-7 removal ( figure  1B) and reduced the proportion of CD12r T cells ( figure 1B) .
Cell-surface expression of IL-7R components in patients with HIV-l infection.
Correlation between cell-surface expression of IL-7R components and plasma IL-7 levels.
The association between plasma IL-7 levels and changes in T cell subsets were examined before therapy in healthy volunteers, patients with PHI, and patients with CHI. Plasma IL-7 levels positively correlated with Survival and turnover of CD12r13T T cells. The large proportion of both CD4+ and CD8+ CD12T T cells prompted us to define the survival and turnover characteristics of these cells. We examined the expression of antiapoptotic protein Bcl-2, a necessary component for T cell survival and a known target of IL-7, and of the cell-cycle protein Ki-67. HIV-1 infection was associated with an increase in CD12TBcl-T and CD12TKi-6r CD4+ and CD8+ T cells, which is consistent with the results of previous work [42] (data not shown).
Perturbations in T cell expression of IL-7R in patients with LTNP before and after loss of viral control.
Despite normal CD4+ T cell counts, patients with LTNP-c displayed an increased proportion of CD4+12T132+ T cells at cohort entry, compared with healthy volunteers (median, 8%; P< .05), suggesting that this perturbation occurs first among CD4+ T cells after HIV-1 infection. Interestingly, at cohort entry, patients with LTNP-loc had increased CD12T132+ (median, 19%; P< .01) and decreased CD4+12r13T (median, 13%; P< .01) T cell subsets. These changes occurred in both the CD4+RO-subset and the CD4+RO+ subset (table 3) pression of IL-7R on CD8+ T cells, compared with healthy volunteers, at cohort entry. Patients with LTNP, as a whole, displayed decreased CD8+12r132+ (median, 16%; P< .001) and CD8+127+132-(median, 23%; P< .05) T cell counts and increased CD8+12T13Y (median, 10%; P< .001) and CD8+12T132-(median, 5%; P< .01) T cell counts. These alterations were all significantly different at cohort entry, compared with those of healthy volunteers, indicating that perturbations in the CD8+ T cell subset were independent of those in the CD4+ compartment (data not shown).
DISCUSSION
Is the IL-7/IL-7R system a central T cell regulatory path that is used in lymphopenia to drive restoration of immunity? Or are increased plasma IL-7levels merely a result oflymphopenia, which further down-regulates receptor expression, resulting in a malfunctioning system? These questions outline the central direction of current research with regard to IL-7 and require answers to confidently advance laboratory science to therapeutic use. pression of IL-7R on CD8+ T cells, compared with healthy volunteers, at cohort entry. Patients with LTNP, as a whole, displayed decreased CD8+12r132+ (median, 16%; P< .001) and CD8+127+132-(median, 23%; P< .05) T cell counts and increased CD8+12T13Y (median, 10%; P< .001) and CD8+12T132-(median, 5%; P< .01) T cell counts. These alterations were all significantly different at cohort entry, compared with those of healthy volunteers, indicating that perturbations in the CD8+ T cell subset were independent of those in the CD4+ compartment (data not shown).
Is the IL-7/IL-7R system a central T cell regulatory path that is used in lymphopenia to drive restoration of immunity? Or are increased plasma IL-7levels merely a result oflymphopenia, which further down-regulates receptor expression, resulting in a malfunctioning system? These questions outline the central direction of current research with regard to IL-7 and require answers to confidently advance laboratory science to therapeutic use. The present experiments were used to study the effects of exogenous 11.-7 on 11.-7R expression in vitro. We sought to understand how dysregulation of the 11.-7/11.-7R system relates to disease progression and immune reconstitution, using a spectrum of HIV-l-infected hosts: patients with PHI, patients with CHI, and 2 groups of patients with I.TNP (those who maintained viral control and those who subsequently lost viral control).
CD4+127-132+ and CD4+12J+132-T cell populations in patients with primary HIV-1 infection (PHI). chronic HIV-1 infection (CHI). or long-term nonprogressive HIV-1 infection (LTNP).
Population
We have confirmed a previous report that plasma 11.-7 levels are increased in patients with PHI [43] and have shown that, if ART is implemented, there is normalization of plasma 11.-7 levels in patients with PHI but not in patients with CHI. This is most likely due to the fact that patients with PHI commenced ART with higher total and naive CD4+ T cell counts and were, therefore, more likely have their T cell counts return to the normal range [44] . This reasoning is supported by the finding that patients with I.TNP who had CD4+ T cell counts within the normal range did not have increased plasma 11.-7 levels, although disease progression and loss of viral control were associated with increased plasma 11.-7 levels, compared with cohort-entry levels. Plasma 11.-7 levels inversely correlated with total and naive CD4+ T cell counts in patients with CHI but not in patients with PHI. This suggests that, although 11.-7 was up-regulated in patients with PHI, increased levels that inversely correlate to lymphocyte populations appear to be a phenomenon of chronic disease.
A recent study found that baseline plasma 11.-7 levels positively correlate with CD4+ T cell immune reconstitution over 20 months of ART [25] . However, we found that baseline plasma 11.-7 level predicted ART-associated CD4+ T cell immune reconstitution (between these 2 measurements there was a positive correlation over 10 months) in patients with PHI but not in patients with CHI. The difference in study design may explain the conflicting results. The present study had a larger sample size and a shorter observation period. The previous study involved a heterogenous patient group whose CD4+ T cell count on average was consistent with that of patients with CHI. One possible explanation is that the positive relationship between plasma 11.-7 levels and an increase in CD4+ T cell counts emerges in a shorter time frame in patients with PHI and that it requires>10 months in patients with CHI.
In the examination of age as a confounding factor between our PHI cohort and our older, CHI cohort, we found no evidence indicating that baseline plasma 11.-7 levels were significantly correlated with age, which is in concordance with the results of the largest cross-sectional analysis of plasma 11.-7 levels [19] . There has been a report that plasma 11.-7 levels inversely correlate with age in patients with late-stage HIV-l disease for whom ART has failed [45] , but the cohort in that study was very different in terms of disease stage.
We found substantial evidence indicating that there is differential regulation of cell-surface expression of the 11.-7R components associated with plasma 11.-7 levels both in vitro and in vivo. This regulation occurs via distinct pathways; this finding is similar to those of previous reports regarding the 11.-2 receptor [46] . In vitro, 11.-7 markedly down-regulated CD127 and up-regulated CD132 expression over 7 days. The sustained down-regulation of CD127 occurred after a threshold of 10 ng/ ml. was reached. At the highest concentration, down-regulation occurred within hours, and thet:e was no reexpression unless the 11.-7 was removed. Cell-surface expression relied on de novo protein synthesis. This finding complements work done in murine models by Park et al. [35] . Inhibition of de novo protein synthesis also decreased the proportion of CD12r T cells, suggesting a constitutive rate of CD127 turnover on the surface of quiescent cells. Inherent to this work, however, is the assumption that local 11.-7 concentrations in lymphoid niches are significantly greater than levels detected in plasma, because of the propensity of 11.-7 to bind to the extracellular matrix [47] [48] [49] .
There is evidence of a CD127 internalization pathway [50] ; The present experiments were used to study the effects of exogenous 11.-7 on 11.-7R expression in vitro. We sought to understand how dysregulation of the 11.-7/11.-7R system relates to disease progression and immune reconstitution, using a spectrum of HIV-l-infected hosts: patients with PHI, patients with CHI, and 2 groups of patients with I.TNP (those who maintained viral control and those who subsequently lost viral control).
There is evidence of a CD127 internalization pathway [50] ; however, permeabilization of both fresh cultured and thawed PBMCs resulted in no increase in detection of CD127 but did result in a large increase in detection of CD132 expression. If internalized, CD127 may be rapidly degraded or stored in an impermeable vesicle. In contrast, it is believed that CD132 mRNA is constitutively expressed [51] and stored intracellulady before translocation to the surface [52, 53] . We confirmed large intracellular stores of mature CD132 that are not depleted in patients with CHI. Four distinct subpopulations of CD4+ and CD8+ T cells could be distinguished on the basis of cell-surface IL-7R component expression. HIV-l infection was associated with a net loss of CDI27+13T T cells and an increase of the CDI2T132+ subset, which correlated with absolute CD4+ T cell count. These changes were evident in both the CD45RO-and the CD45RO+ subsets. Additionally, HIV-l infection was associated with a marked loss of the CD8+127+132+ subset, illustrating that regulation of the IL-7/IL-7R system is distinct between CD4+ and CD8+ T cells. Loss of CD127 from the CD8+127+132+ subset may have been due to down-regulation of CD127 during antigen-driven proliferation and may explain why, in patients with HIV-l infection, loss of CD127 was first recognized in CD8+ T cells [32] . CD12T T cells displayed decreased Bcl-2 expression and increased turnover in CD4+ and CD8+ populations, indicating that these cells were dividing and short-lived.
Patients with LTNP, as a whole, had altered expression of IL-7R in the CD8+ subset. Increased CD4+12T132+ cell counts were evident in patients with LTNP-c, suggesting that some changes in IL-7R expression are inevitable during HIV-1 infection. Loss of CD4+127+13T subsets preceded the loss of viral control in patients with LTNP-loc, illustrating that depletions in these populations may relate to disease progression. Overall, the finding that patients with LTNP have normal plasma IL-7 levels but altered receptor expression suggests that decreases in CD127 expression may initially precede an increase of circulating IL-7 during HIV-l infection, but CD127 was then further down-regulated by its ligand.
Further work in this area should focus on the mechanism by which IL-7 modulates expression of its receptor components and the distinct functional properties of these novel CD4+ and CD8+ subsets. Certainly the success of IL-7 therapy as a vaccine adjuvant or promoter of immune reconstitution will rely on more information regarding whether target cells respond to IL-7 with the desired survival and proliferation signals or whether the presence of exogenous IL-7 results in further loss of receptor expression.
however, permeabilization of both fresh cultured and thawed PBMCs resulted in no increase in detection of CD127 but did result in a large increase in detection of CD132 expression. If internalized, CD127 may be rapidly degraded or stored in an impermeable vesicle. In contrast, it is believed that CD132 mRNA is constitutively expressed [51] and stored intracellulady before translocation to the surface [52, 53] . We confirmed large intracellular stores of mature CD132 that are not depleted in patients with CHI.
Four distinct subpopulations of CD4+ and CD8+ T cells could be distinguished on the basis of cell-surface IL-7R component expression. HIV-l infection was associated with a net loss of CDI27+13T T cells and an increase of the CDI2T132+ subset, which correlated with absolute CD4+ T cell count. These changes were evident in both the CD45RO-and the CD45RO+ subsets. Additionally, HIV-l infection was associated with a marked loss of the CD8+127+132+ subset, illustrating that regulation of the IL-7/IL-7R system is distinct between CD4+ and CD8+ T cells. Loss of CD127 from the CD8+127+132+ subset may have been due to down-regulation of CD127 during antigen-driven proliferation and may explain why, in patients with HIV-l infection, loss of CD127 was first recognized in CD8+ T cells [32] . CD12T T cells displayed decreased Bcl-2 expression and increased turnover in CD4+ and CD8+ populations, indicating that these cells were dividing and short-lived.
